If you are a pet owner, veterinarian or animal health professional who cares for dogs, you think about parasite prevention often. Fleas, ticks, heartworms and intestinal worms are a very real threat to a dog's health and the appropriate product can make a huge difference. Afoxolaner and milbemycin oxime chewable tablets are now one of the most trusted dual-action antiparasitic products in the market today. In this post we'll take a detailed look at why these tablets are used in dogs, how they function and what makes them stand out from the crowd in the crowded veterinary parasite management industry.
Afoxolaner And Milbemycin Oxime Chewable Tablets
1.General Specification(in stock)
(1)API(Pure powder)
(2)Tablet
9.375+1.875mg：2-3.5kg
18.75+3.75mg：＞3.5-7.5kg
37.5+7.5mg：＞7.5-15kg
75+15mg：＞15-30kg
150+30mg：＞30-60kg
(3)Ointment
2.Customization:
We will negotiate individually, OEM/ODM, No brand, for secience researching only.
Internal Code: BM-2-117
Main market: USA, Australia, Brazil, Japan, Germany, Indonesia, UK, New Zealand , Canada etc.
Manufacturer: BLOOM TECH Xi'an Factory
What Are Afoxolaner and Milbemycin Oxime Chewable Tablets Used for in Dogs?
A Dual-Action Formula Designed for Comprehensive Parasite Coverage
Afoxolaner and milbemycin oxime chewable tablets are an oral veterinary medicinal product exclusively for dogs. The product contains two pharmacologically separate active substances in a single monthly chewable dose. Afoxolaner is an isoxazoline class insecticide and acaricide, while milbemycin oxime is a macrolide anthelmintic. Together they attack both external parasites, like as fleas and ticks, and inside parasites, including heartworms and gastrointestinal nematodes. Clinical results show that afoxolaner is present at peak plasma concentrations within 2–4 hours after oral administration, with a plasma half-life of ~2 weeks.
The components of milbemycin oxime, A3 and A4, peak within 1–2 hours, have half-lives of 1.6 and 3.3 days, respectively, and provide sustained protection throughout the monthly dosage cycle.
Who Should Consider This Product?
For healthy canines 2kg and above, over 8 weeks of age. This product is available in five weight-based dose regimens, from 9.375 mg afoxolaner + 1.875 mg milbemycin oxime for dogs weighing 2 to 3.5 kg to 150 mg afoxolaner + 30 mg milbemycin oxime for dogs weighing 30 to 60 kg. Veterinarians often employ this medicine as a first-line defense against parasites in high-risk conditions, including as in rescue shelters and in families with several pets.
Afoxolaner and Milbemycin Oxime Chewable Tablets for Flea and Tick Control
How Afoxolaner Targets External Parasites
Afoxolaner works by blocking the gamma-aminobutyric acid (GABA)-gated chloride ion channels in arthropods. By inhibiting these channels, the chloride ions are unable to move, leading to uncontrolled neuronal hyperexcitation in the target pest. The result is rapid paralysis and death of fleas and ixodid ticks. A major pharmacologic advantage of afoxolaner is the remarkable receptor selectivity, with a much higher affinity to the arthropod GABA receptor than to the mammalian receptor. This provides the basis for the good safety profile of afoxolaner in dogs. Studies have showed that afoxolaner starts killing fleas within hours of ingestion and is a fast-acting option for dogs with an active infestation.
Why Monthly Oral Dosing Outperforms Topical Alternatives
Afoxolaner and milbemycin oxime chewable tablets are absorbed into the bloodstream to provide protection systemically, whereas topical spot-on medications are dispersed on the surface of your dog's skin and may be affected by washing or swimming. The treatment is taken directly into the circulation so external parasites are exposed to afoxolaner when they bite and feed on the dog. This mechanism of action eliminates the irregularities associated with topical applications with coatings. The oral formulation allows for more consistent and predictable coverage, especially for swimming dogs or dogs in humid climates. The palatability design of the tablet also encourages compliance with therapy, since dogs are more likely to accept the chewable version without resistance.
How Afoxolaner and Milbemycin Oxime Chewable Tablets Help Control Internal Parasites
Milbemycin Oxime's Mechanism Against Nematodes and Heartworms
Milbemycin oxime works differently as an antiparasitic than afoxolaner. It binds to the glutamate-gated chloride ion channels of the nerve and muscle cells of invertebrates . This increases the membrane permeability and causes the cell to hyperpolarize . This hyperpolarization results in paralysis and death of vulnerable internal parasites like Dirofilaria immitis (heartworm larvae), gastrointestinal roundworms, hookworms and whipworms. In animals milbemycin oxime is poorly permeable across the blood-brain barrier. The low density of relevant receptors in the canine central nervous system suggests that the drug is without neurological influence on the host animal.
Bioavailability Data Supporting Clinical Confidence
The absolute bioavailability of milbemycin oxime A3 is 81 % and of A4 65 % following oral dosing. These data are from published pharmacokinetic studies and show consistent systemic absorption to justify regular monthly dosage. The tissue distribution volume of each of the components is in the range of 2.6–2.7 L/kg, demonstrating extensive tissue penetration reaching parasites in many organ systems. This pharmacokinetic profile supports the use of afoxolaner and milbemycin oxime chewable tablets by veterinary practitioners needing predictable clinical performance supported by data.
Afoxolaner and Milbemycin Oxime Chewable Tablets for Heartworm and Intestinal Nematode Protection
Preventing Heartworm Disease in Dogs
Heartworm disease is caused by the parasite Dirofilaria immitis and is transmitted by mosquito bites. Without treatment, it can cause major harm to the cardiovascular system of dogs. Milbemycin oxime has been demonstrated to be particularly effective against the L3 and L4 larval stages of heartworm and monthly dosing with afoxolaner and milbemycin oxime chewable tablets is an effective means of prevention. Veterinarian recommendations typically include year-round heartworm prevention in locations where mosquitoes are endemic, including parts of North America, Australia, Brazil, Japan and Southeast Asia. Clinical field trial results support the use of this formulation as a safe and reliable monthly heartworm preventive for dogs living under these circumstances.
Gastrointestinal Nematode Control in Routine Canine Care
Milbemycin Oxime not only prevents the development of heartworm disease, but also gives a detectable level of protection against several common intestinal parasites like Toxocara canis, Ancylostoma caninum, and Trichuris vulpis. These nematodes are amongst the most common parasites of the domestic dog around the globe and some have the potential to transmit zoonotic illnesses which might impact on human health in certain circumstances. For dog owners, a single chewable dose per month that treats both internal and external parasites streamlines multi-product regimens and improves overall parasite management outcomes.
Why Choose Afoxolaner and Milbemycin Oxime Chewable Tablets for Broad Parasite Control?
The Advantage of a Single Monthly Dose for Full-Spectrum Protection
Parasite prevention is difficult to manage, sometimes doses are missed and it's more expensive when so many different therapies are utilized. Afoxolaner and milbemycin oxime chewable tablets, a convenient oral chewable tablet, once a month, provides flea control, tick control, heartworm prevention and intestinal deworming. This consolidation is clinically relevant, decreasing treatment gaps that might arise when owners juggle multiple administration regimes. This combination formulation presents a streamlined strategy that will be particularly helpful for shelter managers, breeding institutions and other large-scale veterinary specialists and pet care providers.
Safety Profile and Breed-Specific Considerations
This formulation is well established to have a safety data profile in most dog breeds. MDR1 (ABCB1) gene mutations (confirmed or suspected - most often observed in Collies and related herding breeds) may lead to greater quantities of milbemycin oxime due to decreased P-glycoprotein function. Not for use in some breeds of dog without consulting your doctor. Not for use in puppies under 8 weeks of age or weighing less than 2 kg. Pregnant or lactating dogs should be carefully assessed by a qualified veterinarian prior to treatment. The pharmacologic selectivity of both active components in these and other groups provides a wide safety margin for broad clinical use.
Proven Market Acceptance and Global Distribution
The formulation has made substantial inroads into the U.S., Australia, Brazil, Japan, Germany, Indonesia, U.K., New Zealand and Canada global markets. It has undergone comprehensive regulatory review, as indicated by its registration history (first import certifying in 2018 and successful re-registration in 2023). Market data suggests that this product category comprises more than 30% of the global canine deworming market share, particularly in places where heartworm is endemic. This degree of adoption indicates genuine veterinary and consumer confidence, underpinned by clinical results and consistent product quality.
Conclusion
Afoxolaner and milbemycin oxime chewable tablets are a scientifically verified, clinically validated choice for total parasite prevention in dogs. A palatable monthly chewable tablet formulation containing a fast-acting isoxazoline insecticide and a proven macrolide anthelmintic for the treatment and prevention of all life stages of fleas and ticks, and for the treatment and management of heartworm disease and intestinal worms in dogs. The pharmacokinetic data, regulatory approval history, and global clinical use all demonstrate why this treatment is essential to appropriate canine parasite management.
Frequently Asked Questions
Q1: Are afoxolaner and milbemycin oxime chewable tablets safe for all dog breeds?
+
-
When given according to the weight-based dosing recommendations, the medication is safe for most breeds of dogs. Milbemycin oxime may be more prone to cause serious neurologic effects in Rough Collies and other dogs with mutations in the MDR1 gene, due to accumulation of the drug. Under these conditions, breed-specific risk should be assessed by a veterinarian prior to starting treatment.
Q2: How often should afoxolaner and milbemycin oxime chewable tablets be given to dogs?
+
-
Given once monthly as usual. Monthly injection provides plasma concentrations of both active ingredients that are sufficient to provide protection against fleas, ticks, heartworm larvae and intestinal nematodes throughout the dosing period.
Q3: Can afoxolaner and milbemycin oxime chewable tablets be used alongside other veterinary medications?
+
-
Milbemycin oxime is a substrate for P-glycoprotein (P-gp) Concomitant dosing with other P-gp substrates (eg digoxin or some macrolide antibiotics) may alter medication concentrations and raise risk of adverse effects. Do not combine this medicine with other pharmaceuticals unless you have first checked with a professional veterinarian.
Partner with Bloomtechz - Your Trusted Afoxolaner and Milbemycin Oxime Chewable Tablets Supplier
Bloomtechz has been a trusted afoxolaner and milbemycin oxime chewable tablets manufacturer, offering support for pharmaceutical distributors, veterinary wholesalers, and R&D organizations in over 20 countries. Our GMP certified manufacturing site with 100,000 square meters has passed onsite inspections by US FDA, EU GMP agencies, PMDA, MFDS and BGV-Hamburg Germany. Each batch is triple-tested for quality: at the factory level, by our own in-house QA/QC department and by a professionally authorized Chinese authority agency for third-party analysis. OEM/ODM customization. Order quantity is flexible and price is clear with a fixed appropriate profit margin for long term cooperation. If you are sourcing afoxolaner and milbemycin oxime chewable tablets for bulk buying, private labeling or formulation research, our staff is ready to support your goals with accurate lead times, comprehensive documentation for customs clearance and dedicated account management. Contact us today at Sales@bloomtechz.com, we answer fast and are eager to create a sustainable supply connection with you.
References
1. Dryden, M. W., Payne, P. A., Smith, V., & Hostetler, J. (2013). Efficacy of afoxolaner against Ctenocephalides felis infestations on dogs. Veterinary Parasitology, 201(3–4), 207–211.
2. Taenzler, J., Rainer, B., Wengenmayer, C., & Fankhauser, R. (2014). Efficacy of afoxolaner against Ixodes ricinus tick infestations in dogs. Parasites & Vectors, 7, 503.
3. Robertson-Plouch, C., Baker, K. A., Hozak, R. R., Zimmermann, A. G., & Herr, C. (2000). Clinical field study of milbemycin oxime for prevention of heartworm disease and control of intestinal parasites in dogs. Journal of the American Veterinary Medical Association, 216(2), 198–202.
4. Prichard, R. K., & Roulet, A. (2007). ABC transporters and beta-tubulin in macrocyclic lactone resistance: prospects for marker development. Parasitology, 134(8), 1123–1132.
5. Becskei, C., Geurden, T., Maeder, S., Kühnert, P., & Meli, M. L. (2017). Comparative speed of kill of afoxolaner and milbemycin oxime combination against fleas and ticks on dogs in a controlled laboratory study. Parasitology Research, 116(Suppl 1), 45–52.
6. European Medicines Agency. (2022). Assessment report: Afoxolaner and milbemycin oxime combination veterinary medicinal products for dogs - Committee for Medicinal Products for Veterinary Use. European Medicines Agency, Amsterdam.